secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001655759-25-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas updates Phase 3 vepdegestrant combo trials; VERITAC-2 topline data expected Q1 2025
--------------------------------------------------------------------------------

- Topline data for VERITAC-2 Phase 3 monotherapy trial of vepdegestrant expected in Q1 2025.
- First-line Phase 3 combo with Pfizer's atirmociclib planned for 2025; VERITAC-3 (palbociclib combo) discontinued.
- Phase 1 trial of ARV-102 (LRRK2 degrader) in Parkinson's disease initiated; data at AD/PD conference April 2025.
- Alex Santini appointed interim CCO effective Jan 17, 2025; John Northcott leaving for personal reasons.
- IND filing for KRAS G12D degrader and initial data from ARV-393 (BCL6 degrader) expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/0001655759-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/arvn-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer